Related Experiment Videos
Points to be considered for conducting toxicokinetic studies under GLP and for validating analytical methods
T Yuzuriha1, K Aizawa, J Okada
1Pharmaceutical Regulatory Audit & Compliance Department, Eisai Co., Ltd, Tokyo, Japan.
The Journal of Toxicological Sciences
|December 1, 1996
Summary
Implementing toxicokinetic (TK) studies requires careful management, especially when TK measurements are separate from toxicity studies. Ensuring validated analytical methods and revalidation upon condition changes are crucial for reliable toxicokinetic data.
Area of Science:
- Pharmacology and Toxicology
- Drug Development
- Regulatory Science
Background:
- Implementation of International Council for Harmonisation (ICH) guidelines for toxicokinetics (TK) presents practical challenges.
- Coordination between toxicity studies and TK measurements, often conducted by separate entities, requires specific management strategies.
Purpose of the Study:
- To summarize key issues identified by the Japan Pharmaceutical Manufacturers Association (JPMA) TK Working Group regarding ICH TK guideline implementation.
- To discuss practical challenges and propose countermeasures for managing TK studies in alignment with toxicity studies.
Main Methods:
- Review and summarization of discussions from the JPMA TK Working Group.
- Identification of critical points in TK study management and analytical method validation.
Main Results:
- A unique management system is recommended for TK studies when TK measurements are performed separately from toxicity studies.
- TK measurements must adhere to validated protocols and Standard Operating Procedures (SOPs) for analytical methods.
- Revalidation of analytical methods is necessary when study conditions in toxicity studies or TK measurements change.
Conclusions:
- Effective implementation of ICH TK guidelines necessitates robust management systems and rigorous adherence to validated analytical procedures.
- Proactive identification and mitigation of practical issues are essential for ensuring the integrity and reliability of toxicokinetic data in drug development.